RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

Benzinga · 1d ago
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.